|Other Names||E3 ubiquitin-protein ligase TRIM32, 632-, 72 kDa Tat-interacting protein, Tripartite motif-containing protein 32, Zinc finger protein HT2A, TRIM32, HT2A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13287a was selected from the N-term region of TRIM32. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Has an E3 ubiquitin ligase activity. Ubiquitinates DTNBP1 (dysbindin) and promotes its degradation. May ubiquitinate BBS2. May play a significant role in mediating the biological activity of the HIV-1 Tat protein in vivo. Binds specifically to the activation domain of HIV-1 Tat and can also interact with the HIV-2 and EIAV Tat proteins in vivo.|
|Cellular Location||Cytoplasm. Note=Localized in cytoplasmic bodies, often located around the nucleus|
|Tissue Location||Spleen, thymus, prostate, testis, ovary, intestine, colon and skeletal muscle|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a member of thetripartite motif (TRIM) family. The TRIM motif includes threezinc-binding domains, a RING, a B-box type 1 and a B-box type 2,and a coiled-coil region. The protein localizes to cytoplasmicbodies. The protein has also been localized to the nucleus, whereit interacts with the activation domain of the HIV-1 Tat protein.The Tat protein activates transcription of HIV-1 genes. [providedby RefSeq].
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Liu, Y., et al. J. Invest. Dermatol. 130(5):1384-1390(2010)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Markson, G., et al. Genome Res. 19(10):1905-1911(2009)van Wijk, S.J., et al. Mol. Syst. Biol. 5, 295 (2009) :
If you have any additional inquiries please email technical services at email@example.com.